Modulation of the GABAergic pathway for the treatment of fragile X syndrome

References

• BelmonteMKBourgeronTFragile X syndrome and autism at the intersection of genetic and neural networksNat Neurosci20069101221122517001341
   PubMed Web of Science ®Google Scholar
• BretherickKLFlukerMRRobinsonWPFMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failureHum Genet2005117437638216078053
   PubMed Web of Science ®Google Scholar
• HagermanRHagermanPAdvances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndromeLancet Neurol201312878679823867198
   PubMed Web of Science ®Google Scholar
• BourgeoisJASeritanALCasillasEMLifetime prevalence of mood and anxiety disorders in fragile X premutation carriersJ Clin Psychiatry201172217518220816038
   PubMed Web of Science ®Google Scholar
• WinarniTIChonchaiyaWSumekarTAImmune-mediated disorders among women carriers of fragile X premutation allelesAm J Med Genet A2012158a102473248122903889
   PubMed Web of Science ®Google Scholar
• AuJAkinsRSBerkowitz-SutherlandLPrevalence and risk of migraine headaches in adult fragile X premutation carriersClin Genet201384654655123373759
   PubMed Web of Science ®Google Scholar
• HamlinAASukharevDCamposLHypertension in FMR1 premutation males with and without fragile X-associated tremor/ataxia syndrome (FXTAS)Am J Med Genet A2012158A61304130922528549
   PubMed Web of Science ®Google Scholar
• SullivanSDWeltCShermanSFMR1 and the continuum of primary ovarian insufficiencySemin Reprod Med2011290429930721969264
   PubMed Web of Science ®Google Scholar
• CondeVPalomarFJLamaMJAbnormal GABA-mediated and cerebellar inhibition in women with the fragile X premutationJ Neurophysiol201310951315132223236003
   PubMed Web of Science ®Google Scholar
• FarzinFPerryHHesslDAutism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutationJ Dev Behav Pediatr200627Suppl 2S137S14416685180
   PubMed Web of Science ®Google Scholar
• LeighMJSHagermanRJHesslDFragile X SyndromeHansenRLRogersSJAutism and Other Neurodevelopmental DisordersArlingtonAmerican Psychiatric Publishing20135776
   Google Scholar
• CoffeeBKeithKAlbizuaIIncidence of fragile X syndrome by newborn screening for methylated FMR1 DNAAm J Hum Genet200985450351419804849
   PubMed Web of Science ®Google Scholar
• CrawfordDCAcuñaJMShermanSLFMR1 and the fragile X syndrome: human genome epidemiology reviewGenet Med20013535937111545690
   PubMed Web of Science ®Google Scholar
• SorensenPLGaneLWYarboroughMHagermanRJTassoneFNewborn screening and cascade testing for FMR1 mutationsAm J Med Genet A20131611596923239591
   PubMed Web of Science ®Google Scholar
• AllenEGHeWYadav-ShahMShermanSLA study of the distributional characteristics of FMR1 transcript levels in 238 individualsHum Genet2004114543944714758538
   PubMed Web of Science ®Google Scholar
• LudwigALEspinalGMPrettoDICNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat sizeHum Mol Genet Epub2112014
   Web of Science ®Google Scholar
• BhakarALDölenGBearMFThe pathophysiology of fragile X (and what it teaches us about synapses)Annu Rev Neurosci20123541744322483044
   PubMed Web of Science ®Google Scholar
• BrownVJinPCemanSMicroarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndromeCell2001107447748711719188
   PubMed Web of Science ®Google Scholar
• BearMFHuberKMWarrenSTThe mGluR theory of fragile X mental retardationTrends Neurosci200427737037715219735
   PubMed Web of Science ®Google Scholar
• MoySSNadlerJJAdvances in behavioral genetics: mouse models of autismMol Psychiatry200813142617848915
   PubMed Web of Science ®Google Scholar
• RubensteinJMerzenichMModel of autism: increased ratio of excitation/inhibition in key neural systemsGenes Brain Behav20032525526714606691
   PubMed Web of Science ®Google Scholar
• BagniCTassoneFNeriGHagermanRFragile X syndrome: causes, diagnosis, mechanisms, and therapeuticsJ Clin Invest2012122124314432223202739
   PubMed Web of Science ®Google Scholar
• FatemiSFolsomTRooneyRThurasPmRNA and protein expression for novel GABAA receptors θ and ρ2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathwayTransl Psychiatry201336e27123778581
   PubMed Web of Science ®Google Scholar
• DölenGCarpenterRLOcainTDBearMFMechanism-based approaches to treating fragile XPharmacol Ther20101271789320303363
   PubMed Web of Science ®Google Scholar
• Berry-KravisEKnoxAHerveyCTargeted treatments for fragile X syndromeJ Neurodev Disord20113319321021484200
   PubMed Web of Science ®Google Scholar
• PadgettCLSlesingerPAGABAB receptor coupling to G-proteins and ion channelsAdv Pharmacol20105812314720655481
   PubMedGoogle Scholar
• FarrantMNusserZVariations on an inhibitory theme: phasic and tonic activation of GABA(A) receptorsNat Rev Neurosci20056321522915738957
   PubMed Web of Science ®Google Scholar
• CardinJACarlénMMeletisKDriving fast-spiking cells induces gamma rhythm and controls sensory responsesNature2009459724766366719396156
   PubMed Web of Science ®Google Scholar
• WangLWBerry-KravisEHagermanRJFragile X: leading the way for targeted treatments in autismNeurotherapeutics20107326427420643379
   PubMed Web of Science ®Google Scholar
• SohalVSZhangFYizharODeisserothKParvalbumin neurons and gamma rhythms enhance cortical circuit performanceNature2009459724769870219396159
   PubMed Web of Science ®Google Scholar
• Berry-KravisEGrossmanAWCrnicLSGreenoughWTUnderstanding fragile X syndromeCurrent Paediatrics2002124316324
   Google Scholar
• HagermanRJBerry-KravisEKaufmannWEAdvances in the treatment of fragile X syndromePediatrics2009123137839019117905
   PubMed Web of Science ®Google Scholar
• AduseiDCPaceyLKChenDHampsonDREarly developmental alterations in GABAergic protein expression in fragile X knockout miceNeuropharmacology201059316717120470805
   PubMed Web of Science ®Google Scholar
• LiaoCWLienCEstimating intracellular Ca2+ concentrations and buffering in a dendritic inhibitory hippocampal interneuronNeuroscience200916441701171119782725
   PubMed Web of Science ®Google Scholar
• Olmos-SerranoJLPaluszkiewiczSMMartinBSKaufmannWECorbinJGHuntsmanMMDefective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndromeJ Neurosci201030299929993820660275
   PubMed Web of Science ®Google Scholar
• CuriaGPapouinTSéguélaPAvoliMDownregulation of tonic GABAergic inhibition in a mouse model of fragile X syndromeCereb Cortex20091971515152018787232
   PubMed Web of Science ®Google Scholar
• D’HulstCHeulensIBrouwerJRExpression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS)Brain Res2009125317618319070606
   PubMed Web of Science ®Google Scholar
• GantoisIVandesompeleJSpelemanFExpression profiling suggests underexpression of the GABAA receptor subunit delta in the fragile X knockout mouse modelNeurobiol Dis200621234635716199166
   PubMed Web of Science ®Google Scholar
• PaceyLKKHeximerSPHampsonDRIncreased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile x knockout mice to audiogenic seizuresMol Pharmacol2009761182419351745
   PubMed Web of Science ®Google Scholar
• KimSYBurrisJBassalFFear-specific amygdala function in children and adolescents on the fragile x spectrum: a dosage response of the FMR1 geneCereb. Cortex201424360061323146966
   PubMed Web of Science ®Google Scholar
• GibsonJRBartleyAFHaysSAHuberKMImbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndromeJ Neurophysiol200810052615262618784272
   PubMed Web of Science ®Google Scholar
• Berry-KravisEMHesslDRathmellBEffects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trialSci Transl Med20124152152ra127
   PubMed Web of Science ®Google Scholar
• EricksonCAWengNWeilerIJOpen-label riluzole in fragile X syndromeBrain Res2011138026427021059347
   PubMed Web of Science ®Google Scholar
• EricksonCAWinkLARayBImpact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndromePsychopharmacology (Berl)20132281758423436129
   PubMed Web of Science ®Google Scholar
• CarterRBWoodPLWielandSCharacterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3β-hydroxy-3β-methyl-5α-pregnan-20-one), a selective, high-affinity, steroid modulator of the γ-aminobutyric acidA receptorJ Pharmacol Exp Ther19972803128412959067315
   PubMed Web of Science ®Google Scholar
• KerriganJFShieldsWDNelsonTYGanaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trialEpilepsy Res200042213313911074186
   PubMed Web of Science ®Google Scholar
• HeulensID’HulstCVan DamDDe DeynPPKooyRFPharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse modelBehav Brain Res2012229124424922285772
   PubMed Web of Science ®Google Scholar
• D’HulstCDe GeestNReeveSPDecreased expression of the GABAA receptor in fragile X syndromeBrain Res20061121123824517046729
   PubMed Web of Science ®Google Scholar
• ChangSBraySMLiZIdentification of small molecules rescuing fragile X syndrome phenotypes in DrosophilaNat Chem Biol20084425626318327252
   PubMed Web of Science ®Google Scholar
• PieriboneVATsaiJSouffletCClinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsyEpilepsia200748101870187417634060
   PubMed Web of Science ®Google Scholar
• Marinus PharmaceuticalsGanaxolone Treatment in Children With Fragile X Syndrome Available from: http://clinicaltrials.gov/ct2/show/NCT01725152. NLM identifier: NCT01725152Accessed March 24, 2014
   Google Scholar
• NusserZModyISelective modulation of tonic and phasic inhibitions in dentate gyrus granule cellsJ Neurophysiol20028752624262811976398
   PubMed Web of Science ®Google Scholar
• CopeDWHughesSWCrunelliVGABAA receptor-mediated tonic inhibition in thalamic neuronsJ Neurosci20052550115531156316354913
   PubMed Web of Science ®Google Scholar
• BrownNKerbyJBonnertTWhitingPWaffordKPharmacological characterization of a novel cell line expressing human alpha(4)beta(3) delta GABA(A) receptorsBr J Pharmacol2002136796597412145096
   PubMed Web of Science ®Google Scholar
• WohlfarthKMBianchiMTMacdonaldRLEnhanced neurosteroid potentiation of ternary GABA(A) receptors containing the delta subunitJ Neurosci20022251541154911880484
   PubMed Web of Science ®Google Scholar
• HaasKFMacdonaldRLGABAA receptor subunit gamma2 and delta subtypes confer unique kinetic properties on recombinant GABAA receptor currents in mouse fibroblastsJ Physiol1999514Pt 127459831714
   PubMed Web of Science ®Google Scholar
• DengPYRotmanZBlundonJAFMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channelsNeuron201377469671123439122
   PubMed Web of Science ®Google Scholar
• Olmos-SerranoJLCorbinJGBurnsMPThe GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndromeDev Neurosci201133539540322067669
   PubMed Web of Science ®Google Scholar
• EgawaKKitagawaKInoueKDecreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of angelman syndromeSci Transl Med20124163163ra157
   PubMed Web of Science ®Google Scholar
• BrowneTRPharmacokinetics of antiepileptic drugsNeurology1998515 Suppl 4S2S79818917
   PubMed Web of Science ®Google Scholar
• BrowneTSzaboGNew pharmacokinetic methods for the study of antiepileptic medications of the 1990sEpilepsia199032S66S731743172
   PubMed Web of Science ®Google Scholar
• LindbergerMLuhrOJohannessenSILarssonSTomsonTSerum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration studyTher Drug Monit200325445746212883229
   PubMed Web of Science ®Google Scholar
• Podboraczynska-JodkoiKLubinskiWHampel-OsipowiczERetinal dysfunction in patients treated with vigabatrinKlin. Oczna20071091–38588 Polish17687922
   PubMedGoogle Scholar
• HendersonCWijetungeLKinoshitaMNReversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofenSci Transl Med20124152152ra128
   Web of Science ®Google Scholar
• Thomson ReutersKey trial of Seaside autism drug fails to show benefit [press release]New York, NYThomson Reuters201351 Available from: http://www.reuters.com/article/2013/05/01/us-autism-drug-idUSBRE9400NT20130501Accessed May 05, 2014
   Google Scholar
• SansoneSMWidamanKFHallSSPsychometric study of the Aberrant Behavior Checklist in Fragile X Syndrome and implications for targeted treatmentJ Autism Dev Disord20124271377139221972117
   PubMed Web of Science ®Google Scholar
• HeYBenzAFuTNeuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor functionNeuropharmacology200242219920911804616
   PubMed Web of Science ®Google Scholar
• LeachJPBrodieMJNew antiepileptic drugs – an explosion of activitySeizure1995415177788108
   PubMed Web of Science ®Google Scholar
• SuzdakPDJansenJAA review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitorEpilepsia19953666126267555976
   PubMed Web of Science ®Google Scholar
• NielsenEBSuzdakPDAndersenKEKnutsenLJSonnewaldUBraestrupCCharacterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitorEur J Pharmacol199119632572661832636
   PubMed Web of Science ®Google Scholar
• Berry–KravisEEpilepsy in fragile X syndromeDev Med Child Neurol2002441172472812418611
   PubMed Web of Science ®Google Scholar
• National Fragile X FoundationSeaside Therapeutics Announces End of Arbaclofen (STX209) Extension Study [press release]Walnut Creek, CANational Fragile X Foundation2013516 Available from: http://www.fragilex.org/2013/research/news-reports-and-commentaries/seaside-therapeutics-announces-end-of-arbaclofen-stx209-extension-study/Accessed May 06, 2014
   Google Scholar
• Berry-KravisEMechanism-based treatments in neurodevelopmental disorders: fragile X syndromePediatr Neurol201450429730224518745
   PubMed Web of Science ®Google Scholar
• BraatSKooyRFFragile X syndrome neurobiology translates into rational therapyDrug Discovery Today201419451051924508819
   PubMed Web of Science ®Google Scholar
• JacquemontSCurieAdes PortesVEpigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056Sci Transl Med201136464ra1
   PubMed Web of Science ®Google Scholar
• SchneiderALeighMJAdamsPElectrocortical changes associated with minocycline treatment in fragile X syndromeJ Psychopharmacol2013271095696323981511
   PubMed Web of Science ®Google Scholar
• University of California Los AngelesTrial to evaluate the safety of Lovastatin in individuals with neurofibromatosis Type I (NF1) Available from: http://clinicaltrials.gov/show/NCT00352599. NLM identifier: NCT00352599Accessed May 26, 2014
   Google Scholar
• MichalonASidorovMBallardTMChronic pharmacological mGlu5 inhibition corrects fragile X in adult miceNeuron2012741495622500629
   PubMed Web of Science ®Google Scholar
• ChenWMultitouch tabletop technology for people with autism spectrum disorder: a review of the literatureProcedia Comput Sci201214198207
   Google Scholar
• WinarniTISchneiderABorodyanskaraMHagermanRJEarly intervention combined with targeted treatment promotes cognitive and behavioral improvements in young children with fragile x syndromeCase Rep Genet2012201228081323074686
   PubMedGoogle Scholar
• LeighMJNguyenDVMuYA randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndromeJ Dev Behav Pediatr201334314715523572165
   PubMed Web of Science ®Google Scholar
• DziembowskaMPrettoDIJanuszAHigh MMP-9 activity levels in fragile X syndrome are lowered by minocyclineAm J Med Genet A2013161A81897190323824974
   PubMed Web of Science ®Google Scholar
• WirojananJJacquemontSDiazRThe efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndromeJ Clin Sleep Med20095214515019968048
   PubMed Web of Science ®Google Scholar